Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics. Its programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. The companys lead FAK inhibitor, VS-6063, is in Phase I/Ib testing in ovarian cancer, as well as developing for the treatment of mesothelioma and breast cancer. It is also developing FAK inhibitor VS-4718 and PI3K/mTOR inhibitor VS-5584 in patients with advanced cancers. The companys product candidates target CSCs that have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. Verastem, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
April 10, 2023
RegMed Investors (RMi) Research Note: Q4 and FY22 earnings reporting
April 5, 2023
RegMed Investors’ (RMi) closing bell: the cell and gene therapy sector just can’t get a break
March 27, 2023
RegMed Investors’ (RMi) closing bell: a BUY zone or just another algorithm rebound?
March 21, 2023
RegMed Investors’ (RMi) closing bell: an upside after negative actions
March 17, 2023
RegMed Investors’ (RMi) closing bell: a second Black Swan event this week
March 15, 2023
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector suffers from Autophobia
March 8, 2023
RegMed Investors’ (RMi) closing bell: the cell/gene therapy sector opened down, climbed up and then fell back
35 companies, 1 interpreter!
Insight, foresight and recommendation
Verastem (VSTM) -- Opened 2018 at $3.21, started February at $3.55 and March at $3.05 with a high of $3.24 on 3/6 - neeeds news which always stimulates volume and pricing offsetting complacency in share pricing ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors